Method for Testing of Drugs Belonging to Substrates and Inhibitors of the Transporter Protein BCRP on Caco-2 Cells

Q3 Pharmacology, Toxicology and Pharmaceutics
Yu. S. Tranova, A. A. Slepnev, I. V. Chernykh, A. V. Shchulkin, P. Yu. Mylnikov, N. M. Popova, M. I. Povetko, E. N. Yakusheva
{"title":"Method for Testing of Drugs Belonging to Substrates and Inhibitors of the Transporter Protein BCRP on Caco-2 Cells","authors":"Yu. S. Tranova, A. A. Slepnev, I. V. Chernykh, A. V. Shchulkin, P. Yu. Mylnikov, N. M. Popova, M. I. Povetko, E. N. Yakusheva","doi":"10.33380/2305-2066-2023-12-2-87-94","DOIUrl":null,"url":null,"abstract":"Introduction. Breast cancer resistance protein (BCRP) is an efflux membrane transporter that controls the pharmacokinetics of a large number of drugs. Its activity may change when taking some endo- and exogenous substances, thus making it a link in drug interactions. Aim. The aim of the study was to develop a method for testing of drugs for belonging to BCRP substrates and inhibitors in vitro. Materials and methods. The work was performed on Caco-2 cells overexpressing BCRP, the cultivation was performed in a transwell-system consisting of the apical and basolateral chambers. Cells were seeded at the bottom of the apical chamber, which is a semipermeable membrane. Primarily, the transport of BCRP substrates: methotrexate, mitoxantrone and quercetin was evaluated in the concentration range of 1, 5, 10, and 50 μM in the direction from the basal chamber to the apical one (Papp b-a) and in the opposite direction (Papp a-b). The ratio Papp b-a / Papp a-b more than «2» characterizes the participation of transporter proteins in the transcellular transport of substances. To confirm the participation of BCRP in their transport the experiment was carried out with the addition of a transporter inhibitor, reserpine, to the transport medium at a concentration of 50 μM. The concentration of substrates in the chambers was analyzed by HPLC-MS/MS. Results and their discussion. The addition of methotrexate (1 μM), mitoxantrone (1 μM), and quercetin (1–10 μM) to both the apical or basolateral chambers of the transwell-system, their content in the recipient chamber was not detected. When methotrexate concentration became 5 μM the Papp b-a / Papp a-b ratio was 3.38 ± 0.08, which indicates the involvement of transporters in its transfer. The addition of methotrexate to the donor chamber at concentrations of 10 and 50 μM, Papp b-a / Papp a-b decreased to values below «2». At mitoxantrone concentration of 5 μM Papp b-a / Papp a-b was 2.72 ± 0.16. An increase in the concentration to 10 μM led to an increase in Papp b-a / Papp a-b to 6.18 ± 0.08. With a substance content of 50 μM the indicator decreased but remained above the value «2». In the quercetin concentration of 50 microns, Papp b-a / Papp was below \"2\". Reserpine reduced Papp b-a / Papp a-b of methotrexate by 3.31 times ( p = 0.0002), which indicates the elimination of asymmetry in the transport of the substance. At a mitoxantrone concentration of 10 microns, reserpine reduced its Papp b-a / Papp a-b by 3.36 times ( p < 0.0001). The results indicate the participation of BCRP in the control of the transfer of both substances through the cellular monolayer. Conclusion. A method of testing drugs belonging to BCRP substrates and inhibitors using methotrexate (5 μM) and mitoxantrone (10 μM) as marker substrates and reserpine (50 μM) as inhibitor was developed and tested on Caco-2 cells.","PeriodicalId":36465,"journal":{"name":"Drug Development and Registration","volume":"222 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development and Registration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33380/2305-2066-2023-12-2-87-94","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Breast cancer resistance protein (BCRP) is an efflux membrane transporter that controls the pharmacokinetics of a large number of drugs. Its activity may change when taking some endo- and exogenous substances, thus making it a link in drug interactions. Aim. The aim of the study was to develop a method for testing of drugs for belonging to BCRP substrates and inhibitors in vitro. Materials and methods. The work was performed on Caco-2 cells overexpressing BCRP, the cultivation was performed in a transwell-system consisting of the apical and basolateral chambers. Cells were seeded at the bottom of the apical chamber, which is a semipermeable membrane. Primarily, the transport of BCRP substrates: methotrexate, mitoxantrone and quercetin was evaluated in the concentration range of 1, 5, 10, and 50 μM in the direction from the basal chamber to the apical one (Papp b-a) and in the opposite direction (Papp a-b). The ratio Papp b-a / Papp a-b more than «2» characterizes the participation of transporter proteins in the transcellular transport of substances. To confirm the participation of BCRP in their transport the experiment was carried out with the addition of a transporter inhibitor, reserpine, to the transport medium at a concentration of 50 μM. The concentration of substrates in the chambers was analyzed by HPLC-MS/MS. Results and their discussion. The addition of methotrexate (1 μM), mitoxantrone (1 μM), and quercetin (1–10 μM) to both the apical or basolateral chambers of the transwell-system, their content in the recipient chamber was not detected. When methotrexate concentration became 5 μM the Papp b-a / Papp a-b ratio was 3.38 ± 0.08, which indicates the involvement of transporters in its transfer. The addition of methotrexate to the donor chamber at concentrations of 10 and 50 μM, Papp b-a / Papp a-b decreased to values below «2». At mitoxantrone concentration of 5 μM Papp b-a / Papp a-b was 2.72 ± 0.16. An increase in the concentration to 10 μM led to an increase in Papp b-a / Papp a-b to 6.18 ± 0.08. With a substance content of 50 μM the indicator decreased but remained above the value «2». In the quercetin concentration of 50 microns, Papp b-a / Papp was below "2". Reserpine reduced Papp b-a / Papp a-b of methotrexate by 3.31 times ( p = 0.0002), which indicates the elimination of asymmetry in the transport of the substance. At a mitoxantrone concentration of 10 microns, reserpine reduced its Papp b-a / Papp a-b by 3.36 times ( p < 0.0001). The results indicate the participation of BCRP in the control of the transfer of both substances through the cellular monolayer. Conclusion. A method of testing drugs belonging to BCRP substrates and inhibitors using methotrexate (5 μM) and mitoxantrone (10 μM) as marker substrates and reserpine (50 μM) as inhibitor was developed and tested on Caco-2 cells.
Caco-2细胞上转运蛋白BCRP底物和抑制剂药物的检测方法
介绍。乳腺癌耐药蛋白(Breast cancer resistance protein, BCRP)是一种外排膜转运蛋白,控制着大量药物的药代动力学。它的活性在服用一些内源性和外源性物质时可能发生变化,从而使其成为药物相互作用的一个环节。的目标。本研究的目的是开发一种在体外测试属于BCRP底物和抑制剂的药物的方法。材料和方法。这项工作是在过表达BCRP的Caco-2细胞上进行的,培养是在由顶室和基底侧室组成的transwell系统中进行的。细胞在顶室底部播种,顶室为半透膜。首先,在1、5、10和50 μM的浓度范围内,测定BCRP底物甲氨蝶呤、米托蒽醌和槲皮素在基底室向顶室方向(Papp b-a)和相反方向(Papp a-b)的转运情况。Papp b-a / Papp a-b比值大于“2”表征转运蛋白参与物质的跨细胞转运。为了证实BCRP参与了它们的转运,实验在转运介质中加入了转运抑制剂利血平,浓度为50 μM。采用高效液相色谱-质谱联用(HPLC-MS/MS)分析培养皿中底物的浓度。结果和讨论。将甲氨蝶呤(1 μM)、米托蒽醌(1 μM)和槲皮素(1 ~ 10 μM)分别添加到transwell系统的顶腔和底侧腔中,均未检测其在受体腔中的含量。当甲氨蝶呤浓度为5 μM时,Papp b-a / Papp a-b比值为3.38±0.08,表明转运蛋白参与了其转运。在供体腔中添加浓度为10 μM和50 μM的甲氨蝶呤,Papp b-a / Papp a-b降至«2»以下。在米托蒽醌浓度为5 μM时,Papp b-a / Papp a-b为2.72±0.16。当浓度增加到10 μM时,Papp b-a / Papp a-b增大到6.18±0.08。当物质含量为50 μM时,该指标有所下降,但仍保持在“2”以上。在槲皮素浓度为50 μ m时,Papp b-a / Papp低于“2”。利血平使甲氨蝶呤的Papp b-a / Papp a-b降低了3.31倍(p = 0.0002),表明消除了物质转运中的不对称性。在米托蒽醌浓度为10微米时,利血平使其pap b-a / pap a-b降低3.36倍(p <0.0001)。结果表明,BCRP参与控制这两种物质通过细胞单层的转移。结论。建立了以甲氨蝶呤(5 μM)和米托蒽醌(10 μM)为标记底物,利血平(50 μM)为抑制剂检测BCRP底物和抑制剂药物的方法,并在Caco-2细胞上进行了实验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Development and Registration
Drug Development and Registration Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
1.20
自引率
0.00%
发文量
61
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信